Vor Bio (VOR) posted clinical data and commercial ambitions for its lead drug telitacicept at a Wells Fargo biotech conference, outlining a strategy to capture outsized share of the myasthenia gravis (MG) market despite currently low biologic penetration.
The company, valued at approximately $1.48 billion with shares trading around $25.05 after a 66% advance over the past six months, presented phase III readout timelines, formulation development plans, and competitive positioning for telitacicept across multiple autoimmune indications.
Telitacicept, developed jointly with RemeGen, simultaneously inhibits BAFF and APRIL with a two-to-one potency ratio favoring BAFF. In clinical studies involving roughly 3,000 patients, the drug reduced total IgG by approximately 30% while cutting double-stranded DNA antibodies by about 70%, without prompting discontinuations due to hypogammaglobulinemia. Jeremy Sokolove, Vor Bio's chief medical officer, said the dual-mechanism approach provides "additivity of upstream and downstream mechanisms" compared with APRIL-dominant competitors such as batoclimab.
For MG, Vor Bio completed enrollment in its pivotal phase III study, with data expected in spring 2027. An ocular MG trial is planned for the first half of the year. Phase II data from China showed a 4.8- to 5.7-point reduction on the MG-Activities of Daily Living scale, exceeding the 4.0- to 4.5-point improvements typically seen with approved therapies. Sokolove cautioned that global placebo responses are expected to run in the 2- to 3-point range, higher than the roughly 1-point placebo response observed in the China study, but added that he expects the treatment effect to remain proportionate.
"If we come close to replicating the Chinese data, you are looking at a drug that is double the efficacy of the entire rest of the field," said Dallan Murray, Vor Bio's chief commercial officer. Only 20% to 30% of MG patients currently receive biologic therapy, representing a significant untapped market.
The company is also advancing telitacicept in Sjögren's disease and IgA nephropathy (IgAN), using both a 160 mg and a 240 mg dose. The U.S. Sjögren's enrollment closed within six months of study start, and a phase III trial there is 96% powered for a 2- to 2.5-point change on the primary endpoint. The current formulation requires two prefilled syringes once weekly, with a higher-concentration version under development to enable a single syringe; an auto-injector is also in the pipeline but not expected at launch.
Wall Street analysts have set price targets between $27 and $50 on the stock.
